יומירה 40 מ"ג

Pays: Israël

Langue: hébreu

Source: Ministry of Health

Ingrédients actifs:

ADALIMUMAB 40 MG / 0.8 ML

Disponible depuis:

ABBVIE BIOPHARMACEUTICALS LTD, ISRAEL

Code ATC:

L04AA17

forme pharmaceutique:

SOLUTION FOR INJECTION

Composition:

PEN

Mode d'administration:

S.C

Fabriqué par:

ABBVIE LTD, UK

Groupe thérapeutique:

ADALIMUMAB

indications thérapeutiques:

* Rheumatoid arthritis: Humira in combination with methotrexate is indicated for: - the treatment of moderate to severe active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate. - the treatment of severe active and progressive rheumatoid arthritis in adults not previously treated with methotrexate. Humira can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. Humira has been shown to reduce the rate of progression of joint damage as measured by X-ray adn to impove physical function when given in combination with methotrexate. * Crohn's disease : Humira is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active Crohn's disease who have had an inadequate response to conventional therapy.Humira is indicated for reducing signs and symptoms and inducing clinical r

Date de l'autorisation:

2009-07-01